Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Tacrolimus capsules (0.5mg, 1mg), which are potent immunosuppressants used to prevent organ rejection after liver or kidney transplants [1] Group 1 - The Tacrolimus capsules were originally submitted for registration by Jiangsu Hechen Pharmaceutical Co., Ltd. in June 2024 and received a drug registration acceptance number [1] - During the review period, there was a change in the drug registration applicant, with the company becoming the marketing authorization holder [1] - The drug was approved on January 2026, and it is considered to have passed the consistency evaluation of quality and efficacy for generic drugs [1]